PDCD1 and non-small cell lung carcinoma: Reports have suggested that fewer than half of all NSCLC patients have a TPS of 50% or greater70, implying that a majority of NSCLC patients fail to realize enhanced clinical benefit from PD-1/PD-L1 blockade over traditional chemotherapy.